Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pushkala Aripaka"


21 mentions found


REUTERS/Henry Nicholls/File PhotoEurope's drug regulator on Friday identified another rare blood condition as a potential side effect of AstraZeneca's (AZN.L) COVID-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots. The European Medicines Agency's (EMA) safety committee said that capillary leak syndrome must be added as a new side effect to labelling on AstraZeneca's vaccine, known as Vaxzevria. People who had previously sustained the condition, where fluids leak from the smallest blood vessels causing swelling and a drop in blood pressure, should not receive the shot, the EMA added. Last month, the EMA had advised against using the second AstraZeneca shot for people with that clotting condition, known as thrombosis with thrombocytopenia syndrome (TTS). The committee reviewed six validated cases of capillary leak syndrome in people, mostly women, who had received Vaxzevria, including one death.
Persons: Henry Nicholls, BioNTech Organizations: AstraZeneca, REUTERS, Medicines, EMA, European Union, Pfizer, Health Ministry, Moderna, BioNTech, Thomson Locations: Westfield Stratford City, London, Britain, Liechtenstein, Iceland, Norway, United States, Israel
REUTERS/Dylan Martinez/File PhotoBritish online trading group CMC Markets (CMCX.L) on Thursday set out plans to launch a wealth management platform, going head to head with existing players such as Hargreaves (HRGV.L) and AJ Bell (AJBA.L), after reporting a doubling in annual profits. CMC, which facilitates the trade of complex financial instruments, raised its outlook multiple times this year as a retail trading boom fuelled volumes. Rivals IG (IGG.L) and Plus500 (PLUSP.L) have also reported strong results, powered partly by the "GameStonk" retail trading phenomenon. read more'UNDERCUT THE MARKET'The GameStonk effect has been most visible in the United States, where online brokers such as Robinhood have thrived on the back of a retail trading boom. The company did not disclose further details on its planned wealth platform, first reported by Sky News, but Cruddas was confident of its prospects.
Persons: Dylan Martinez, Hargreaves, AJ Bell, Peter Cruddas, David Fineberg, Cruddas Organizations: CMC Markets, REUTERS, CMC, Reuters, Rivals, GameStop, Sky News, Thomson Locations: London, Britain, United States
AstraZeneca moves finance chief to new role after Alexion deal
  + stars: | 2021-06-04 | by ( Pushkala Aripaka | ) www.reuters.com + 0.00   time to read: +3 min
read moreDunoyer will replace Ludwig Hantson as boss of United States-based Alexion on completion of the agreed deal, with the proposed switch allowing Aradhana Sarin to move in the opposite direction and become AstraZeneca chief financial officer. read moreLondon-listed AstraZeneca said Sarin's appointment is also conditional upon completion of the Alexion deal, which was approved by shareholders last month. read moreAs well as becoming Alexion chief executive, Dunoyer will also be appointed chief strategy officer at AstraZeneca. SHAKE-UPSIndia-born Sarin would become the first woman to take up the CFO role at AstraZeneca on a permanent basis. AstraZeneca declined to comment and a representative for Alexion could not be reached for comment outside business hours.
Persons: Phil Noble AstraZeneca, Marc Dunoyer, Pascal Soriot, Dunoyer, Ludwig Hantson, Soriot, Leif Johansson, we've, Marc, AstraZeneca's Johansson, Alexion's, Hantson, David Brennan Organizations: AstraZeneca, REUTERS, Swedish drugmaker, European Union, Financial, UPS, Barclays, LinkedIn, Alexion, Thomson Locations: Macclesfield, Britain, United States, Swedish, UPS India
UK regulator reviewing AstraZeneca's $39 bln Alexion buyout
  + stars: | 2021-05-25 | by ( Pushkala Aripaka | ) www.reuters.com sentiment -0.99   time to read: +2 min
Britain's competition regulator is reviewing AstraZeneca's (AZN.L) planned $39 billion takeover of U.S.-based Alexion (ALXN.O) on whether it could reduce competition in Britain or other markets. read moreAstraZeneca's European peers Roche (ROG.S) and Novartis (NOVN.S) also have a portfolio of drugs for rare diseases and immunology products. Shareholders of the Cambridge, UK-based company cleared the proposed deal at a general meeting earlier this month where 99.89% of votes cast were in favour of approving it. AstraZeneca, whose stock was 0.3% lower at 8,127 pence by 1112 GMT, is hoping an improved version of Alexion's best-selling drug and other rare-disease medicines will help build a deeper hold in China and other emerging markets. Boston, Massachusetts-based Alexion was not available for comment outside of business hours.
Persons: Roche, Alexion Organizations: Markets Authority, AstraZeneca, Novartis, CMA, Cambridge, European Union, Thomson Locations: U.S, Britain, Swedish, UK, United States, Canada, Brazil, Russia, Japan, China, Boston , Massachusetts
(Reuters) -AstraZeneca shareholders narrowly approved Chief Executive Pascal Soriot’s proposed pay package on Tuesday, after investor advisory groups said its rewards were excessive. REUTERS/Brenda Goh/File PhotoAt its annual investor meeting, 60.19% of votes cast were in favour of approving the new remuneration policy, AstraZeneca said, acknowledging that a “meaningful proportion” were against. Soriot’s total pay package for 2020 of 15.4 million pounds ($21.7 million) was roughly unchanged from 2019. Soriot's salary last year compares to J&J CEO Alex Gorsky's near-$30 million pay plan which was approved here by shareholders last month, also after some opposition. In a separate meeting, AstraZeneca shareholders approved its planned $39 billion takeover of U.S. group Alexion.
Persons: Pascal Soriot’s, Pascal Soriot, Brenda Goh, Soriot, Glass Lewis, Alex Gorsky's, AstraZeneca Organizations: Reuters, AstraZeneca, REUTERS, Union, Times, Pfizer, U.S Locations: Shanghai, China, London
(Reuters) -AstraZeneca said a “meaningful proportion” of its shareholders voted against CEO Pascal Soriot’s improved pay package on Tuesday, exposing a rift as the drugmaker deals with problems surrounding its COVID-19 vaccine. Soriot’s total pay package for 2020 of 15.4 million pounds ($21.7 million) was roughly unchanged from 2019. Shareholder advisory groups ISS, Glass Lewis and PIRC all recommended that investors vote against Soriot’s pay increase. AstraZeneca’s oncology drug business, in particular, is thriving as its not-for-profit pandemic vaccine is distributed. In a separate meeting, AstraZeneca shareholders approved its planned $39 billion takeover of U.S. group Alexion.
Persons: Pascal Soriot’s, Pascal Soriot, Brenda Goh, AstraZeneca, Johnson, Alex Gorsky's, Soriot, Glass Lewis, Marc Dunoyer Organizations: Reuters, AstraZeneca, REUTERS, Union, Johnson, Times, Pfizer, U.S Locations: Shanghai, China, London
(Reuters) -AstraZeneca’s COVID-19 vaccine delivered $275 million in first-quarter sales while shaving three cents per share from earnings, the drugmaker said on Friday as it posted better-than-expected results and forecast second half growth. The vaccine revenue included delivery of about 68 million doses, AstraZeneca said, adding that sales in Europe, where it faces a legal case, were $224 million, in emerging markets $43 million and $8 million in the rest of the world. Sales of $275 million for 68 million doses equates to a price tag of around $4 per shot. AstraZeneca was one of the leaders in the global race to develop a COVID-19 vaccine. Moderna in February said it was expecting sales of $18.4 billion from its own vaccine this year.
Persons: Rachel Wisniewski, Pascal Soriot, AZN’s COVID, BioNTech, GlobalData, AstraZeneca, ” Soriot, Tagrisso, Farxiga Organizations: Reuters, AstraZeneca, REUTERS, Oxford University, , Citigroup, Pfizer, Moderna Locations: North America, Wilmington , Delaware, U.S, Europe
(Reuters) -AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares. It said the revenue included delivery of about 68 million doses, adding that European sales were $224 million, emerging markets $43 million and $8 million in the rest of the world. Sales of $275 million for 68 million doses equates to a price tag of around $4 per shot. AstraZeneca was one of the leaders in the global race to develop a COVID-19 vaccine. “Shipments (of COVID-19 vaccines) are increasing as manufacturing improves,” Soriot said during a briefing, adding that it was on track to deliver 200 million doses a month.
Persons: Rachel Wisniewski, Pascal Soriot, Swedish drugmaker, ” Soriot, , , AZN’s COVID, BioNTech, GlobalData, Soriot, Tagrisso, Farxiga Organizations: Reuters, AstraZeneca, REUTERS, Union, Oxford University, Citigroup, Pfizer, Moderna Locations: North America, Wilmington , Delaware, U.S, Swedish, Europe
GSK said that turnover for the three months to March fell 15% to 7.42 billion pounds ($10.28 billion) at constant currency rates, while adjusted earnings stood at 22.9 pence per share. Analysts had expected adjusted earnings of 21.9 pence per share and sales of 7.83 billion pounds, a company-compiled consensus of 17 analysts showed. GSK last year launched the split plan, which involves merging its over-the-counter products business into a venture with Pfizer (PFE.N) and separating this from its prescription medicines and vaccines units. Investments to prepare for this have hurt earnings, but GSK hopes the streamlined operations will pay off in the long term. "I'm very focused on leading GSK through that successful separation and beyond," Walmsley said during a conference call following the release of GSK's results.
Persons: Matthew Childs, British drugmaker, Emma Walmsley, Elliott, Walmsley Organizations: GlaxoSmithKline, Stevenage, REUTERS, GSK, GlaxoSmithKline Plc, Pfizer, Investments, Thomson Locations: Britain, British
The separation was spearheaded by Walmsley, a former head of GSK's consumer business, to simplify operations. Analysts had expected adjusted earnings of 21.9 pence per share and sales of 7.83 billion pounds, a company-compiled consensus of 17 analysts showed. Walmsley launched GSK's split, which involves merging its over-the-counter products business into a venture with Pfizer (PFE.N) and separating this from its prescription medicines and vaccines units, last year. Investments to prepare for the division have hurt earnings, but GSK hopes the streamlined operations resulting from it will pay off in the long term. Walmsley said that while GSK's consumer health business had great prospects and a "fantastic" leadership team, she would seek to remain in control of the bigger picture.
Persons: Matthew Childs, Elliott, British drugmaker, Emma Walmsley, Walmsley, Steve Clayton, Hargreaves, GSK's, " Walmsley Organizations: GlaxoSmithKline, Stevenage, REUTERS, GSK, Analysts, Pfizer, Investments, Thomson Locations: Britain, British
REUTERS/Matthew Childs/File PhotoPlans for GSK to split in two are "well underway" it said on Wednesday, as a cost clampdown and rising clinic visits for critical treatments after an easing of COVID-19 curbs helped it land better-than-forecast first-quarter earnings. Chief Executive Emma Walmsley said she was focused on GSK's broader transformation, adding that while GSK's consumer health business had great prospects and a "fantastic" leadership team, she would focus on the bigger picture. Walmsley, a former head of GSK's consumer business, became CEO in 2017 despite some investor pressure to name an outsider and such calls may grow with Elliott's arrival on the register. Preparations have hurt earnings, but GSK hopes the streamlining of operations will pay off in the long term. However, GSK expects its vaccines division to recover in the second half, as healthcare systems and consumer trends "approach normality."
Persons: Matthew Childs, Elliott, British drugmaker, Emma Walmsley, Walmsley, I've, " Walmsley, Steve Clayton, Hargreaves, Sebastian Skeet Organizations: GlaxoSmithKline, Stevenage, REUTERS, GSK, Sanofi, Novartis, Thomson Locations: Britain, British
Vaccines, management in focus as GSK, AstraZeneca report
  + stars: | 2021-04-26 | by ( Pushkala Aripaka | ) www.reuters.com + 0.00   time to read: +3 min
The logo of the German branch of British-Swedish pharmaceutical company AstraZeneca is pictured in Wedel near Hamburg, Germany, March 1, 2021. AstraZeneca was one of the leaders in the global race to develop a COVID-19 vaccine but has faced a series of controversies. Use began early this year, and AstraZeneca has said it will not profit from the vaccine while COVID-19 is being treated as a pandemic. read more"Despite vaccine headwinds and headlines, (AstraZeneca) remains a top pick," Leerink analysts said in a note. For its part, GSK, the world's biggest vaccines maker by sales, has focused on supplying its vaccine booster to other COVID-19 shot developers and helping to produce their jabs.
Persons: Cathrin Mueller, Elliott, Johnson, Pascal Soriot, Sanofi, GSK's, Emma Walmsley, Walmsley Organizations: AstraZeneca, REUTERS, Cathrin Mueller GlaxoSmithKline, AstraZeneca Plc, GSK, FOCUS AstraZeneca, Oxford University, JPMorgan, Alexion, Barclays, Thomson Locations: British, Swedish, Wedel, Hamburg, Germany, divestments
The lift from demand for COVID-19 related products and from acquisitions offset a 5% fall in sales from the company’s other offerings, however, and Bunzl maintained its annual guidance. Bunzl closed three acquisitions in the first quarter and expects that momentum to continue, Chief Executive Frank van Zanten told Reuters. “We use our cash flow to pay dividends, so we have a lot of capacity for making acquisitions,” he said. “Others may see a short-term recovery eclipsing Bunzl’s performance, but beyond this the group remains well placed,” they said. (Reporting by Vishwadha Chander and Pushkala Aripaka in Bengaluru; Editing by Krishna Chandra Eluri and Jan Harvey)
Persons: Bunzl, Frank van Zanten, , , Van Zanten, Vishwadha Chander, Pushkala, Krishna Chandra Eluri, Jan Harvey Organizations: Reuters, Shore Capital Locations: Netherlands, Bengaluru
(Reuters) - Europe’s drug regulator said on Friday that it is reviewing rare blood clots in four people in the United States who received Johnson & Johnson’s COVID-19 vaccine. FILE PHOTO: A nurse draws from a vial of Johnson & Johnson coronavirus disease (COVID-19) vaccine, in Los Angeles, California, U.S., March 25, 2021. Johnson & Johnson (J&J) said it was aware of the rare reports of blood clots in individuals given its COVID-19 vaccine, and was working with regulators to assess the data and provide relevant information. The report from the European Medicines Agency is the first to mention a probe of blood clots associated with the J&J vaccine. It follows a probe of blood clots in the brain reported in people given the AstraZeneca vaccine that have caused some European countries to change their vaccine recommendations.
Persons: Johnson, Johnson’s, Lucy Nicholson, Janssen, Ian Douglas, It’s, we’ve, , Jesse Goodman Organizations: Reuters, United States, REUTERS, Medicines, European Medicines Agency, U.S . Centers for Disease Control, U.S . Food, Drug Administration, AstraZeneca, London School of Hygiene, Tropical Medicine, AZ, EU, Regulators, Georgetown University, Washington D.C, J Locations: United, Los Angeles , California, U.S, United States, Europe, Asia, Washington
(Reuters) -Europe’s drug regulator said it is reviewing reports of rare blood clots in four people who received Johnson & Johnson’s COVID-19 vaccine and has expanded its probe into AstraZeneca’s shot to include reports of a bleeding condition. It was the first news of EMA’s probe of the J&J vaccine, while AstraZeneca’s coronavirus vaccine has been dogged for weeks over possible links to rare blood clots in the brain and abdomen, which the EMA has confirmed. U.S.-based J&J said that it was aware of the reports of blood clots possibly related to its COVID-19 vaccine and others, and is working with regulators to assess the data and provide relevant information. “At present, no clear causal relationship has been established between these rare events and the Janssen COVID-19 vaccine,” the company said in an emailed statement. The EMA also said five cases of capillary leak syndrome linked to AstraZeneca’s vaccine were reported.
Persons: Johnson, Johnson’s, Janssen, J Organizations: Reuters, European Medicines Agency, EMA, EU, Regulators, AstraZeneca, J Locations: United States, Europe, Asia
AstraZeneca shares fall on "hefty" $39-billion Alexion deal
  + stars: | 2020-12-14 | by ( Pushkala Aripaka | ) www.reuters.com + 0.00   time to read: +2 min
(Reuters) -AstraZeneca shares fell as much as 9% on Monday, as investors moved to price in the costs of a $39 billion deal for U.S. biotech company Alexion Pharmaceuticals that would be the British drugmaker’s biggest ever corporate acquisition. REUTERS/Stefan Wermuth/File PhotoThe deal, announced over the weekend, is also one of the biggest in an already bumper year for mergers and acquisitions and at current market prices will be almost two-thirds funded with AstraZeneca shares. AstraZeneca shares were down 5.9% at 7,676 pence by 1048 GMT, wiping roughly 7 billion pounds ($9.4 billion) off its market value of 107.1 billion pounds, as of its last close. The company would also have to pay AstraZeneca up to $1.2 billion to walk away from the deal. Alexion shares in 2015 traded as high as $200 a share and the deal follows pressure from hedge fund Elliott Management to complete a sale.
Persons: Stefan Wermuth, Cowen, Liberum, Pascal Soriot, Soriot Organizations: Reuters, AstraZeneca, Alexion Pharmaceuticals, British drugmaker’s, REUTERS, Management, Pfizer, Moderna Locations: London
(Reuters) -AstraZeneca will start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot aimed at boosting the efficacy of the British drugmaker’s vaccine, Russia’s sovereign wealth fund said on Friday. FILE PHOTO: A test tube labeled with the vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. TWITTER DIPLOMACYThe partnership came about after the developers of Sputnik V suggested on Twitter last month that AstraZeneca try the combination after the British drugmaker released interim results from its late-stage trial. Still, Russian officials have not always been complimentary about the British vaccine. The news came as Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people.
Persons: Dado, drugmaker, , , Kirill Dmitriev, Kate Bingham, Dmitry Peskov, Sputnik Organizations: Reuters, AstraZeneca, Sputnik, REUTERS, Gamaleya, Pfizer, Moderna, Twitter, British drugmaker, Gamaleya Institute, Oxford University, Kremlin, Sanofi, GlaxoSmithKline Locations: Russia, Soviet, Moscow, Western, Russian, U.S, British
(Reuters) - AstraZeneca will start clinical trials to test a combination of its experimental COVID-19 vaccine with Russia’s Sputnik V shot aimed at boosting the efficacy of the British drugmaker’s vaccine, Russia’s sovereign wealth fund said on Friday. Slideshow ( 2 images )Trials will start by the end of the year, said the RDIF wealth fund, which has funded Sputnik V, named after the Soviet-era satellite that triggered the space race. The prospective tie-up comes as AstraZeneca, once seen as a frontrunner in the vaccine race, prepares for further tests to confirm whether its shot could be 90% effective, potentially slowing its rollout. The developers of Sputnik V suggested on Twitter last month that AstraZeneca try the combination. The news came as Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people.
Persons: AstraZeneca, , Kirill Dmitriev Organizations: Reuters, AstraZeneca, Sputnik, Gamaleya, Pfizer, Moderna, Twitter, Kremlin, Sanofi, GlaxoSmithKline Locations: Soviet, Moscow, Western, Russian, U.S, Russia
REUTERS/Darren Staples(Reuters) - Security group G4S on Tuesday agreed to be bought out by Allied Universal for 3.8 billion pounds ($5.08 billion), picking the U.S. company over Canadian rival GardaWorld and potentially ending a tense, months-long bidding war. Allied’s offer of 245 pence per share for London-listed G4S is 10 pence higher than GardaWorld’s sweetened bid from last week, which pegged the British company at 3.7 billion pounds. “The G4S Board is confident in the long-term prospects of the business and believes this (agreed) offer represents an excellent opportunity to create a leading global security company,” G4S chairman John Connolly said in a statement. The British company has restructured its business following a series of setbacks, and the bidding war between the U.S. and Canadian companies for G4S began when GardaWorld made its offers for G4S public on Sept. 14. Since then, G4S shares had gained about 75% in value at Tuesday’s closing price of 255.8 pence, before the deal was announced.
Persons: Darren Staples, G4S, , ” G4S, John Connolly, GardaWorld, Morgan Cazenove, Goldman Sachs, Lazard, Morgan Stanley, Cleary Gottlieb Steen, Hamilton, Freshfields Bruckhaus, Ellis Organizations: HMP, REUTERS, Allied Universal, U.S ., London, British, U.S, Financial, Citi, J.P, Credit Suisse, Moelis, Company, Kirkland Locations: HMP Birmingham, Birmingham, Britain, Linklaters
G4S backs $5.1 billion Allied deal after bid battle
  + stars: | 2020-12-08 | by ( Pushkala Aripaka | Tanishaa Nadkar | ) www.reuters.com + 0.00   time to read: +2 min
(Reuters) - Security group G4S on Tuesday agreed to be bought out by Allied Universal for 3.8 billion pounds ($5.1 billion), picking the U.S. company over Canadian rival GardaWorld and potentially ending a tense, months-long bidding war. REUTERS/Darren StaplesAllied’s offer of 245 pence per share for London-listed G4S is 10 pence higher than GardaWorld’s sweetened bid from last week, which pegged the British company at 3.7 billion pounds. “The G4S Board is confident in the long-term prospects of the business and believes this (agreed) offer represents an excellent opportunity to create a leading global security company,” G4S chairman John Connolly said in a statement. G4S later formally confirmed that it had rejected the GardaWorld bid of 235 pence per share, saying it undervalued the company. Since then, G4S shares had gained about 75% in value at Tuesday’s closing price of 255.8 pence, before the deal was announced.
Persons: Darren Staples Allied’s, G4S, , ” G4S, John Connolly, GardaWorld, Morgan Cazenove, Goldman Sachs, Lazard, Morgan Stanley, Cleary Gottlieb Steen, Hamilton, Freshfields Bruckhaus, Ellis Organizations: Reuters, Allied Universal, U.S ., HMP, REUTERS, London, British, U.S, Financial, Citi, J.P, Credit Suisse, Moelis, Company, Kirkland Locations: HMP Birmingham, Birmingham, Britain, Linklaters
AstraZeneca AZN.L said on Thursday it was holding back deliveries while it awaits the data from late-stage clinical trials in order to maximise the shelf-life of supplies. AstraZeneca and its partner on the project, the University of Oxford, said data from late-stage trials should land this year. The British duo are racing with Pfizer/BioNTech, Moderna and others to publish the first detailed results from large COVID-19 vaccine trials. The company hopes the shot will be effective for at least a year, but only trial data can confirm this. MIXED RESULTSWhile working on the vaccine, AstraZeneca is also making progress on its pipeline of other drugs.
Persons: Dado Ruvic, AstraZeneca AZN.L, Pascal Soriot, Soriot Organizations: Reuters, AstraZeneca, REUTERS, University of Oxford, Pfizer, European Union Locations: Moderna, United States, Europe
Total: 21